Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
Hepatology2013Vol. 58(6), pp. 1918–1929
Citations Over TimeTop 1% of 2013 papers
Michael Fried, Marı́a Buti, Gregory J. Dore, Robert Flisiak, Péter Ferenci, Ira M. Jacobson, Patrick Marcellin, Michael P. Manns, И. Г. Никитин, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Maria Beumont‐Mauviel
Abstract
SMV QD in combination with Peg-IFN and RBV significantly improves SVR rates, compared with Peg-IFN and RBV alone, and allows the majority of patients to shorten their therapy duration to 24 weeks.
Related Papers
- → Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype(2015)4 cited
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 407 EARLY ON-TREATMENT HAEMATOLOGICAL PARAMETERS AND GENOTYPE PREDICT RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN COMBINATION THERAPY IN CHRONIC HEPATITIS C CIRRHOSIS(2011)
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)